

**Amino acid PET in gliomas:** Heiss summarizes the advantages of amino acid PET imaging in precise demarcation of tumors, definition of malignancy and prognosis, detection of recurrences, and identification of responders, as well as new potential in hybrid modalities. . . . . **Page 1219**

**New PET tracers for AD:** Mach provides a focus on molecular imaging, highlighting advances in the neurobiology of Alzheimer disease and describing the ways in which PET can be used to study associated mechanisms of neurodegeneration. . . . . **Page 1221**

**Health technology assessment of PET:** Dahabreh and Gatsonis offer an overview of challenges in comparative effectiveness research in PET and suggest a flexible, multifaceted approach to the choice of research methods . . . . . **Page 1225**

**RCTs and PET:** Siepe and colleagues conduct a systematic review of diagnostic randomized clinical trials involving PET in a single arm to evaluate evidence-based elements needed now and in the future to support clinical decision making. . . . . **Page 1228**

**PET heterogeneity in NSCLC:** Tixier and colleagues compare visual assessment of intratumor <sup>18</sup>F-FDG PET uptake distribution with textural features automated quantification and assess the relative prognostic capabilities in non-small cell lung cancer. . . . . **Page 1235**

**PET/MR in esophageal cancer staging:** Lee and colleagues detail the diagnostic efficacies of endoscopic ultrasonography, CT, PET/MR, and PET/CT imaging for preoperative local and regional staging of esophageal cancer. . . . . **Page 1242**

**SST antagonists and NETs:** Wild and colleagues explore the feasibility of treatment with <sup>177</sup>Lu-labeled somatostatin receptor antagonists in patients with advanced neuroendocrine tumors . . . . . **Page 1248**

**PET in PPGLs:** van Berkel and colleagues ask whether increased uptake of <sup>18</sup>F-FDG in a genetic subset of pheochromocytomas and paragangliomas reflects increased glycolytic activity and is correlated with specific proteins involved in glucose uptake and metabolism. . . . . **Page 1253**

**PET and metabolic grading of NENs:** Ezziddin and colleagues investigate the prognostic potential of whole-body <sup>18</sup>F-FDG PET in patients with inoperable metastatic gastroenteropancreatic neuroendocrine neoplasms . . . . . **Page 1260**

**Labeled leukocyte PET/CT in pancreatitis:** Bhattacharya and colleagues use PET/CT with <sup>18</sup>F-FDG-labeled autologous leukocytes to detect infec-

tion in pancreatic or peripancreatic fluid collections in patients with acute pancreatitis . . . . . **Page 1267**

**CT angiography vs. lung scintigraphy:** Perinakis and colleagues report normalized dose data for maternal radiosensitive organs and embryo/fetus from 256-slice CT pulmonary angiography and compare resulting radiation cancer risk estimates with those from lung perfusion scintigraphy . . . . . **Page 1273**

**Safety analysis of DaTscan:** Grosset and colleagues present a comprehensive analysis of <sup>123</sup>I-ioflupane safety, from early clinical development through more than a decade after first market approval . . . . . **Page 1281**

**Individual performance and <sup>123</sup>I-ioflupane:** Seibyl and colleagues assess the effects of several variables on individual reader diagnostic interpretation of <sup>123</sup>I-ioflupane SPECT imaging in patients with movement disorders or dementia. . . . . **Page 1288**

**Novel tracers for PDE10A brain imaging:** Barret and colleagues report on characterization of 2 new phosphodiesterase 10A radioligands with promise for novel therapies in a variety of neurologic and psychiatric disorders involving striatal function. . . . . **Page 1297**

**Reading parametric <sup>11</sup>C-PIB PET images:** Zwan and colleagues compare parametric imaging methods to determine an optimal approach for visual assessment of parametric Pittsburgh compound-B PET images to detect cortical amyloid deposition . . . . . **Page 1305**

**Radiopharmaceutical adverse events:** Silberstein describes changing patterns of use and adverse events associated with PET and non-PET radiopharmaceuticals and adjunctive nonradioactive pharmaceuticals from 2007 to 2011 . . . . . **Page 1308**

**Cobalt-labeled octreotide analogs:** Thisgaard and colleagues evaluate the biologic effects of novel cobalt-labeled octreotide analogs targeting the somatostatin receptor to identify promising candidates for molecular imaging and Auger electron-based radionuclide therapy . . . . . **Page 1311**

**Hepatic internal dose-toxicity model:** Walrand and colleagues present a model for accurately predicting maximal tolerable dose as a function of microsphere activity and targeted liver volume in selective internal radiation therapy with <sup>90</sup>Y-loaded microspheres . . . . . **Page 1317**

**IL-13PE intracranial biodistribution:** Suzuki and colleagues describe the intracranial distribution of <sup>125</sup>I-labeled interleukin-13 *Pseudomonas* exotoxin

after convection-enhanced delivery in a murine model of glioblastoma multiforme. . . . . **Page 1323**

**PET monitoring of EAE:** de Paula Faria and colleagues explore the use of <sup>11</sup>C-labeled PET imaging of neuroinflammation to monitor disease progression and treatment in an experimental autoimmune encephalomyelitis rat model, with clinical implications for multiple sclerosis. . . . . **Page 1330**

**In vivo quantification of SV2A:** Warnock and colleagues report on animal studies with <sup>18</sup>F-UCB-H, a PET tracer for imaging synaptic vesicle protein 2A, which binds to a promising therapeutic target for epilepsy . . . . . **Page 1336**

**MSC tracking with D<sub>2</sub> receptor PET:** Schönitzer and colleagues determine the feasibility of <sup>18</sup>F-fallypride PET imaging and in vivo monitoring after transplantation of dopamine type 2 receptor-expressing human mesenchymal stem cells . . . . . **Page 1342**

**Cyclotron production of <sup>63</sup>Zn:** DeGrado and colleagues detail production and initial biologic evaluation of <sup>63</sup>Zn for use with PET in exploration of the abnormalities in zinc homeostasis found in many human diseases. . . . . **Page 1348**

**Bone marrow toxicity model:** Sas and colleagues describe a compartmental model of thrombopoiesis and erythropoiesis in bone marrow radiation toxicity, with potential utility in predicting hematologic toxicity in preclinical studies of dose-response relationships in internal radiotherapy . . . . . **Page 1355**

**Radiotracer dose reduction in PET/MR:** Oehmigen and colleagues perform PET/MR quality studies using reduced doses of injected radiotracer in a standardized phantom following the National Electrical Manufacturers Association IQ protocol . . . . . **Page 1361**

**Comparing pinhole and coincidence PET:** Walker and colleagues assess the potential of a preclinical PET system with a clustered-pinhole collimator for simultaneous high-resolution PET and SPECT imaging . . . . . **Page 1368**

**Quad-modality molecular imaging:** Lu and colleagues describe the development of and initial studies with a novel integrated system that includes PET, SPECT, CT, and fluorescence molecular imaging. . . . . **Page 1375**

**Arterial input function quantification:** Lanz and colleagues introduce the use of the vena cava time-activity curve as a minimally invasive alternative for measurement of <sup>18</sup>F-FDG input function in rodents, without the complications associated with repetitive blood sampling . . . . . **Page 1380**